Novo Nordisk's CagriSema Fails to Match Eli Lilly's Zepbound in Weight Loss Trial

Novo Nordisk released highly anticipated late-stage clinical trial data for its next-generation obesity injection, CagriSema. The results indicated that the drug failed to match the weight loss efficacy achieved by Eli Lilly's rival treatment, Zepbound. This development marks a significant setback for the Danish pharmaceutical giant in the increasingly competitive global obesity market. Analysts had expected CagriSema to set a new benchmark, but the trial data suggests it may struggle to gain a competitive edge over existing therapies. Following the announcement, concerns have emerged regarding Novo Nordisk's future market share in the weight-loss sector. Meanwhile, Eli Lilly's position appears strengthened as its flagship drug maintains its lead in clinical performance.